Sermorelin UK legal status
Sermorelin is a GHRH analogue with a historical pharmaceutical pedigree — Geref was approved in the US for paediatric GH-deficiency diagnostics before being discontinued. It is not currently a UK-licensed medicine, and the consumer-market positioning as ‘anti-ageing therapy’ exceeds its evidence base.
Current UK regulatory framing
Sermorelin (GHRH 1-29) is a 29-amino-acid analogue of the biologically active portion of growth-hormone-releasing hormone. The brand Geref had US approval for paediatric GH-deficiency diagnostics; the brand was discontinued and sermorelin is no longer a commercially marketed licensed medicine in the US.
There is no UK marketing authorisation for sermorelin. It is supplied today almost exclusively through research-peptide and US “anti-ageing clinic” channels — neither of which provides a lawful UK supply route for general adult use.
The historical licensed indication vs. the marketed use
The original clinical case for sermorelin was as a GH-stimulation test in paediatric short stature — a diagnostic, not a therapy. The current consumer-market case is “anti-ageing peptide therapy” for adults seeking body-composition or longevity outcomes. The two are different applications; the historical licence does not extend to or validate the current marketing.
The evidence base
Sermorelin does stimulate pituitary GH release; that is well-established. Whether that GH increase produces clinically meaningful long-term outcomes (body composition, recovery, quality of life, longevity) in non-deficient adults is not supported by RCT evidence. The marketed outcomes outpace the published data.
Sport — WADA S2
GHRH analogues including sermorelin fall under S2 of the WADA Prohibited List. Prohibited at all times. Strict liability applies.
What this means in practice
For sellers
Sermorelin sold with anti-ageing or body-composition claims is presented as a medicine. The unlicensed status engages MHRA; the marketing claims engage ASA.
For clinics
A UK “peptide therapy” or “anti-ageing” clinic offering sermorelin is offering an unlicensed substance for a use that doesn’t fit the historical clinical indication and isn’t supported by current trial evidence.
For consumers
Unlicensed-substance risk applies. The historical pharmaceutical provenance of sermorelin is a marketing point, not a regulatory shield.
For athletes
Direct S2 exposure. The historical paediatric-diagnostic licence does not produce a TUE pathway.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Sermorelin — FDA-approved peptide therapy”
The original Geref licence was for paediatric diagnostics and the brand is discontinued. ‘FDA-approved’ is misleading for the current marketed use.
“Reverse the effects of ageing with sermorelin GH therapy”
Marketing claim outside the historical clinical indication. Engages medicinal-product definition for the marketed adult anti-ageing use.
“Prescribed by our US-based anti-ageing physician — UK delivery”
Cross-border supply of an unlicensed medicine into the UK is not exempt from UK rules just because the prescriber is overseas.
“Research-grade sermorelin — discreet shipping”
Consumer-supply presentation. ‘Discreet shipping’ is the wording of unlicensed retail.
Sources & further reading
- MHRA — gov.uk
- Human Medicines Regulations 2012 — legislation.gov.uk
- WADA Prohibited List (S2) — wada-ama.org
- Global DRO — globaldro.com
Frequently asked questions
- Is sermorelin a licensed UK medicine?
- No. Sermorelin had a US licence (Geref) for paediatric GH deficiency diagnostics; the brand has been discontinued. It is not currently licensed by the MHRA or EMA for any indication.
- Is sermorelin prohibited in sport?
- Yes. As a GHRH analogue it falls under S2 of the WADA Prohibited List. Strict liability.
- Can a US ‘anti-ageing clinic’ supply sermorelin to UK patients?
- Cross-border supply of an unlicensed medicine into the UK is not lawful simply because the source clinic operates in another jurisdiction. UK Border Force, the MHRA, and the receiving prescriber (if any) all have a position.
- What's the evidence for ‘sermorelin for anti-ageing’?
- Sermorelin does increase GH release in the short term. Translating that to clinically meaningful anti-ageing outcomes in non-deficient adults is not supported by clinical-trial evidence. The marketed indication is not the historical clinical indication.
- Can a UK clinic prescribe sermorelin?
- There is no UK marketing authorisation to prescribe under. The ‘specials’ framework would need a special clinical need that licensed alternatives can't meet — anti-ageing or body composition use doesn't fit that test.